Physician profile
David S Posnick
NPI 1629333182
$203,143.36
in general payments reported to CMS, 2019-2025
36 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,665 · 2020: $5,961 · 2021: $7,139 · 2022: $9,580 · 2023: $14K · 2024: $47K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Food and Beverage: $27K · Consulting Fee: $12K · Travel and Lodging: $7,097 · Education: $701 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $126,958.49 |
| Food and Beverage | $27,030.88 |
| Consulting Fee | $12,002.50 |
| Travel and Lodging | $7,097.24 |
| Education | $700.67 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $91,959.39 | 2021-2025 | Nemluvio, Aklief |
| Abbvie INC. | $37,907.59 | 2019-2025 | |
| Pfizer INC. | $22,375.79 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $7,460.41 | 2021-2025 | Sotyktu |
| Ucb, INC. | $6,576.74 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $5,150.34 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $4,045.25 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $3,537.09 | 2019-2025 | |
| Amgen INC. | $3,287.75 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $3,190.55 | 2019-2025 | |
| Janssen Biotech, INC. | $2,659.26 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $2,583.02 | 2019-2025 | Ilumya |
| Dermavant Sciences, INC. | $2,264.06 | 2022-2024 | Vtama |
| Lilly USA, LLC | $1,977.98 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $1,699.94 | 2023-2025 | Zoryve |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $1,150.00 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $989.35 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $842.19 | 2019-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $819.68 | 2019-2025 | Dupixent |
| Celgene Corporation | $567.68 | 2019 | |
| Organon LLC | $526.75 | 2024-2025 | Vtama |
| Chugai Pharmaceutical Co., Ltd. | $400.00 | 2021 | |
| Vyne Pharmaceuticals INC. | $215.79 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.58 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $137.45 | 2019-2021 | |
| Almirall LLC | $130.89 | 2023 | Klisyri |
| Genentech USA, INC. | $124.58 | 2021-2022 | |
| Eli Lilly and Company | $89.72 | 2025 | Ebglyss |
| Helsinn Therapeutics (U.S.), INC. | $89.29 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $67.90 | 2023-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.70 | 2021 | |
| Dusa Pharmaceuticals, INC. | $23.60 | 2019 | |
| Biofrontera INC. | $19.36 | 2021 | |
| Organogenesis INC. | $17.78 | 2021 | |
| Strata Skin Sciences, INC. | $17.30 | 2021 | |
| Smith+Nephew, INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Posnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.